Jonathan M. Spergel

Feb 2, 2024 | onlinelibrary.wiley.com | Elaine Siegfried |Lara Lee |Jonathan M. Spergel |Randy Prescilla

1 INTRODUCTION Dupilumab is a human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, as an immunomodulator. Current regulatory labeling recommends completing all age-appropriate immunizations before initiating dupilumab treatment and avoiding live vaccine administration during treatment.1, 2 The LIBERTY AD PRESCHOOL (Part A and B; NCT03346434) study prohibited live attenuated vaccine administration within 4 weeks before the baseline visit and during treatment.

Feb 3, 2023 | jacionline.org | Marc E. Rothenberg |Jonathan M. Spergel |Evan S. Dellon |Larry Borish

Eosinophilic esophagitis (EoE) is a chronic, progressive, type 2 inflammatory disease of the esophagus. Dupilumab, a fully human mAb, blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation. In phase 3 LIBERTY-EoE-TREET (NCT03633617) dupilumab improved histologic, symptomatic, and endoscopic aspects of EoE and was well tolerated.